昆藥集團(600422.SH):做精做優以參苓健脾胃顆粒、舒肝顆粒、香砂平胃顆粒為核心的“昆中藥1381”精品國藥系列
格隆匯5月26日丨有投資者向昆藥集團(600422.SH)提問:公司未來核心打造的產品有哪些?
昆藥集團回覆::未來,公司將緊抓國家中醫藥創新發展戰略以及人口老齡化進程加速兩大契機,聚焦三七產業鏈,加快實現資源整合,“延鏈-補鏈-強鏈”做大做強以三七系列產品為代表的三七產業;同時,深耕精品國藥,推動大品種、打造強品牌,“傳承-創新-發展”做精做優以參苓健脾胃顆粒、舒肝顆粒、香砂平胃顆粒為核心的“昆中藥1381”精品國藥系列。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.